GlassScriptPhysician profile
Leslie J Pollard
NPI 1467494153
$1,344.37
in general payments reported to CMS, 2019-2025
24 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.84 · 2021: $28.36 · 2022: $201 · 2023: $32.77 · 2024: $143 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.66 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $371.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $199.46 | 2021-2025 | |
| Sandoz INC. | $123.77 | 2022 | |
| Abbott Laboratories | $122.46 | 2024-2025 | |
| Pfizer INC. | $74.62 | 2025 | |
| Corcept Therapeutics | $62.11 | 2025 | Korlym |
| Lilly USA, LLC | $42.84 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $31.20 | 2025 | Otezla, Repatha |
| Genzyme Corporation | $31.20 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $30.13 | 2025 | Farxiga |
| Boston Scientific Corporation | $25.48 | 2024 | Wavewriter Alpha Prime 16 |
| Vital Connect, INC | $23.05 | 2025 | Vitalpatch Rtm |
| Phathom Pharmaceuticals, INC. | $22.01 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $21.84 | 2025 | Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.59 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.68 | 2025 | Xifaxan |
| Dexcom, INC. | $18.37 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $18.35 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.47 | 2024 | Jardiance |
| Currax Pharmaceuticals LLC | $15.25 | 2025 | Contrave |
| Amarin Pharma, INC. | $14.69 | 2022 | |
| Irhythm Technologies, INC. | $13.77 | 2022 | |
| Exact Sciences Corporation | $13.60 | 2023 | Cologuard Collection Kit |
| Radius Health, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.